Barbara Haber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11584633/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. Journal of Pediatrics, 2006, 148, 467-474.e1.	1.8	325
2	Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet, The, 2015, 385, 1075-1086.	13.7	281
3	Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet, The, 2015, 385. 1087-1097.	13.7	257
4	Pathology of chronic hepatitis C in children: Liver biopsy findings in the Peds-C Trial. Hepatology, 2008, 47, 836-843.	7.3	163
5	Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. Gastroenterology, 2017, 152, 164-175.e4.	1.3	155
6	Use of Corticosteroids After Hepatoportoenterostomy for Bile Drainage in Infants With Biliary Atresia. JAMA - Journal of the American Medical Association, 2014, 311, 1750.	7.4	153
7	Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: Efficacy, safety, and pharmacokinetics. Hepatology, 2005, 42, 1010-1018.	7.3	152
8	Impact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional Outcomes. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 341-347.	1.8	107
9	Total Serum Bilirubin within 3ÂMonths of Hepatoportoenterostomy Predicts Short-Term Outcomes in Biliary Atresia. Journal of Pediatrics, 2016, 170, 211-217.e2.	1.8	100
10	Efficacy of Fat-Soluble Vitamin Supplementation in Infants With Biliary Atresia. Pediatrics, 2012, 130, e607-e614.	2.1	95
11	Shortâ€duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology, 2017, 65, 439-450.	7.3	71
12	Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. Hepatology, 2017, 66, 736-745.	7.3	67
13	Pegylated interferon for chronic hepatitis C in children affects growth and body composition: Results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology, 2012, 56, 523-531.	7.3	63
14	Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: A retrospective study. Hepatology, 2013, 58, 1580-1586.	7.3	48
15	Coexpression of liver-specific and growth-induced genes in perinatal and regenerating liver: Attainment and maintenance of the differentiated state during rapid proliferation. Hepatology, 1995, 22, 906-914.	7.3	34
16	Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and preâ€existing renal disease. Hepatology Research, 2017, 47, 1340-1345.	3.4	24
17	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. Hepatology, 2018, 67, 2113-2126.	7.3	22
18	Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology, 2011, 53, 1468-1475.	7.3	21

BARBARA HABER

#	Article	IF	CITATIONS
19	Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection. Antiviral Therapy, 2018, 23, 593-603.	1.0	17
20	Longâ€Term Followâ€Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 89-94.	1.8	11
21	Cholestasis: Current Issues and Plan for the Future. Journal of Pediatric Gastroenterology and Nutrition, 2008, 47, 220-224.	1.8	9
22	Hepatitis C, liver transplantation, and why we should consider children separately. Liver Transplantation, 2006, 12, 1042-1043.	2.4	8
23	The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis. Journal of Viral Hepatitis, 2019, 26, 329-336.	2.0	8
24	An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection. Clinical and Molecular Hepatology, 2019, 25, 400-407.	8.9	7
25	Reply:. Hepatology, 2008, 48, 692-692.	7.3	Ο